3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Cancer
6
Neoplasms
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Malignancies Multiple
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Mitomycin
15
Gemcitabine
13
dodecyl maltoside
5
BCG Vaccine
5
erdafitinib
4
apaziquone
4
ALT-803
4
Epirubicin
3
viscum album peptide
2
durvalumab
2
VB4-845
2
Imiquimod
2
Docetaxel
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
pirarubicin
1
pembrolizumab
1
linrodostat
1
hydroxycamptothecinum
1
enfortumab vedotin
1
catumaxomab
1
Water
1
Therapeutics
1
Therapeutic Uses
1
Standard of Care
1
Polysorbates
1
Photochemotherapy
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non-Muscle Invasive Bladder Neoplasms
×
linrodostat
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts